Arzerra ofatumumab regulatory update

FDA granted accelerated approval to a BLA for Arzerra ofatumumab from Genmab and GlaxoSmithKline to treat chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. The approval tri...